Anti-phospho-CDK1 (Tyr15)(C22-65R)
FOR BULK ORDER REQUESTS PLEASE CONTACT US
Description :Rabbit Polyclonal Antibody
Species :Rabbit
Tag :
Expression System:
Sequence :
Specificity :Recognizes the CDK1 protein phosphorylated at tyrosine 15
Cited Applications :WB
Cross Reactivity :Human, Mouse, Rat, Xenopus and Zebrafish
Host :Rabbit, IgG
Immunogen :Synthetic phospho-peptide corresponding to amino acid residues surrounding Tyr15 conjugated to KLH
Purification :Affinity Chromatography
Stability :Store at 4oC (add 0.1% NaN3) for several months, and at -20oC for longer periods. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Sample Data :Western blot of human T47D cells showing specific immunolabeling of the ~34kDa CDK1 phosphorylated at Tyr15 (Control). Treatment with EGF (30 ng per ml for 30 min) caused dephosphorylation of the Tyr15 on CDK1 (Lane 2). The phosphospecificity of this labeling is also shown in the third and fourth lanes (lambda-phosphatase: lambda-Ptase). These blots are identical to the control except that they were incubated in lambda-Ptase (1200 units for 30 min) before being exposed to Anti-phospho-CDK1 (Tyr15). The immunolabeling is completely eliminated by treatment with lambda-Ptase. 
Scientific Background :Cell Division Control protein 1 (CDK1) is a highly conserved protein serine kinase. CDK1 is a catalytic subunit of the conserved eukaryotic protein kinase complex called that M-Phase Promoting Factor, which plays a key role in regulation of the cell cycle (1). CDK1 is essential for the completion of START, the controlling event in the cell cycle that is required to initiate mitosis. The ability of CDK1 to exercise control over the cell cycle is dependent upon the phosphorylation of Tyr15 in cdc2 (2). CDK1 expression in brain has been linked to neurogenesis and apoptosis (3,4). In addition, CDK1 is a potential pharmaceutical target for prostate cancer therapy (5).
References :
1. Maller, J.L.: Mitotic control. Curr Opin Cell Biol 1991 3:269-275.
2. Nakamizo, A. et al: Suppression of cdc2 dephosphorylation at the tyrosine 15 residue during nitrosourea-induced G2M phase arrest in glioblastoma cell lines. J Neurooncol 2002 59:7-13.
3. Konishi Y et al: The E2F-cdc2 cell-cycle pathway specifically mediates activity deprivation-induced apoptosis of postmitotic neurons. J Neurosci 2003 23:1649-1658.
4. Dranovsky, A. et al. cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology. Neurobiol Aging 2001 22:517-528.
5. Rigas, A.C. et al: Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene 2007 Dec 6;26(55):7611-9.
Product Sheets (By Lot #) :
Research Areas :Cancer, Cell Cycle, Ser/Thr Kinases, Cancer, Cell Cycle, Ser/Thr Kinases